Organisation paid for research Program year 2025 Source: CMS Open Payments

Tucson Neuroscience Research

Neither a doctor nor a teaching hospital

Research payments

$626,452

91 payments

Through program year 2025, Tucson Neuroscience Research is reported as receiving $626,452 in research payments, across 91 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $76,216 4
2024 Research $65,740 11
2023 Research $319,300 45
2022 Research $156,515 24
2021 Research $1,931 6
2020 Research $6,750 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Bavarian Nordic A/S $416,507 55 payments
  2. AstraZeneca Pharmaceuticals LP $109,748 5 payments
  3. Ucb SA $70,351 8 payments
  4. Novo Nordisk AS $16,521 17 payments
  5. ACADIA Pharmaceuticals Inc $8,200 2 payments
  6. Global Kinetics USA Corporation $4,525 3 payments
  7. AbbVie, Inc. $600 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 $202,837 20 payments
  2. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $102,523 24 payments
  3. Nct05238025 $99,147 9 payments
  4. A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus $52,070 1 payment
  5. A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $41,878 2 payments
  6. A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinson's Disease $41,051 5 payments
  7. A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ucb0599 in Study Participants With Early Parkinsons Disease $29,300 3 payments
  8. Nn6535-4725 $16,521 17 payments
  9. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $15,800 2 payments
  10. Nct05329220 $12,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record